Matt Bush represents life sciences and technology companies, ranging from startups to publicly held corporations. He is a sought-after advisor in transactional matters ranging from company formation through maturing growth and exit strategy, which includes day-to-day guidance, venture financings, initial public offerings, mergers and acquisitions, SEC disclosures, corporate governance, and aftermarket capital raising. Mr. Bush is the former Chair of the San Diego office’s Corporate Department.
Prior to entering law school, Mr. Bush was a manager with Accenture, where he assisted clients with business process reengineering and enterprise software implementation.
Mr. Bush’s selected IPO, equity offering, and public company representation experience includes the following:
Mr. Bush’s selected deSPAC and reverse merger experience includes the following:
Mr. Bush’s selected strategic merger and acquisition experience includes the following:
Mr. Bush's investment banking clients include BofA Securities, Citigroup, Cowen, Credit Suisse, Evercore, Goldman Sachs, Jefferies, JP Morgan, Leerink Partners, Morgan Stanley, Piper Jaffray, and Stifel.
Mr. Bush’s extensive experience in company formation and venture and crossover financings includes, among others, representation of: Airgain, Crinetics Pharmaceuticals, eFFECTOR Therapeutics, Elevation Pharmaceuticals, Erasca, Exagen, Gossamer Bio, Icosavax, Meritage Pharma, Mineralys, Prometheus Biosciences, Tealium, and Zogenix.
Recognitions include Impact Deal of the Year and Patent Impact Case of the Year.
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Chambers USA recognized the firm’s Mergers & Acquisitions Practice for “world class expertise when it comes to the most challenging transactions.”